Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma

Table 2 Multivariable Cox and logistic regression analyses to evaluate the association between anti-RNA polymerase III antibodies and development of cancers ^a

Variable	Frequency ( n)	Hazard/Odds ratio	95% CI	P-value
2A: Multivariable Cox regression analysis
Age (per 10 years)	1,740 valid	1.46	1.28 to 1.67	<0.001
Male vs. female	299 vs. 1,441	0.83	0.50 to 1.39	0.487
RNAP⁺ vs. RNAP^-	268 vs. 1,472	2.55	1.75 to 3.74	<0.001
2B: Multivariable Cox regression analysis
Age (per 10 years)	1,694 valid	1.43	1.21 to 1.70	<0.001
Male vs. female	294 vs. 1,401	0.93	0.53 to 1.80	0.931
RNAP⁺ vs. RNAP^-	250 vs. 1,445	2.10	1.27 to 3.48	0.004
2C: Logistic regression analysis
Age (per 10 years)	1,617 valid	1.63	1.27 to 2.09	<0.001
Male vs. female	265 vs. 1,352	0.73	0.28 to 1.90	0.514
RNAP⁺ vs. RNAP^-	249 vs. 1,368	5.83	3.11 to 10.92	<0.001

^aCI, Confidence interval; RNAP⁺, positivity for anti-RNA polymerase III antibodies; RNAP^-, anticentromere antibodies, anti-Scl-70, antinuclear antibody-negative and other antibodies. These analyses include all events (row 2A) with total frequency N = 2,177, 437 cases dropped, 128 events, 1,612 censored; events post-systemic sclerosis onset (row 2B) with total frequency N = 2,177, 483 cases dropped, 83 events, 1,611 censored; and for events within 36 months of systemic sclerosis onset (row 2C) with total frequency N = 1,623, 6 missing cases, 42 events.

ISSN: 1478-6362